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1. Introduction 
Angiogenesis, the formation of new blood vessels, is a critical component in the growth and 
metastasis of cancers and has been recognized as an attractive target for anticancer therapy 
(Ferrara, 2002). Among the pro-angiogenic factors, vascular endothelial growth factor 
(VEGF) is recognized as the predominant mediator of angiogenesis in tumor cells (Ferrara & 
Kerbel, 2005). As VEGF is overexpressed in most ovarian cancers, the VEGF pathway is a 
promising target for anti-angiogenic therapy against ovarian cancer (Burger, 2011). 
Recent increases in our understanding of the molecular pathways that control tumor 
angiogenesis have led to the development of novel VEGF-targeting agents for the treatment 
of ovarian cancer (Burger, 2011). In addition to inhibiting neo-vascularization, anti-
angiogenic agents are also believed to normalize intratumoral blood vessels. Intratumoral 
vessels are hyperpermeable, leading to interstitial hypertension and impaired perfusion in 
tumors. Normalization of the tumor vasculature results in a reduction in interstitial pressure 
and the improved delivery of oxygen, nutrients, and cytotoxic agents (Ferrara, 2002).  
Many of these agents have been evaluated in clinical trials, and some of them have shown 
promising clinical activity against ovarian cancer (Burger, 2011). In this article, we review 
the emerging VEGF-targeting strategies for treating ovarian cancer and provide information 
about the latest clinical studies of VEGF-targeting agents that have been employed as 
treatments for ovarian cancer. 
2. Angiogenesis overview 
Angiogenesis is the process by which new blood vessels grow from the existing vasculature. 
A tumor is unable to grow beyond 2mm diameter without neoangiogenesis (Carmeliet, 
2000), thus, angiogenesis plays an essential role in tumor growth, invasion, and metastasis 
(Carmeliet, 2000; Kerbel, 1991). Angiogenesis is tightly regulated by balancing pro- and anti-
angiogenic factors. The transition of a tumor from “avascular phase” to “vascular phase” is 
termed “angiogenic switch”. This switch is believed to be stimulated by an increase in 
expression of pro-angiogenic factors. A variety of pro-angiogenic factors have been 
identified and recognized as potential targets of antiangiogenic therapy (Ferrara & Kerbel, 
2005). Vascular endothelial cell growth factor (VEGF), one of the key mediators of 
angiogenesis, promotes the proliferation, survival, and migration of endothelial cells and is 
essential for blood vessel formation (Ferrara & Kerbel, 2005). VEGF can also affect new 
vessel formation in tumors by acting as a chemoattractant for bone marrow-derived 
progenitor cells (Rafii et al., 2002). The major physiological stimulus for VEGF expression is 
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hypoxia, which commonly develops within tumors when cancer cell proliferation exceeds 
the rate of blood vessel formation. Hypoxia inducible factor-1 (HIF-1), a transcriptional 
activator that acts as a central regulator of oxygen homeostasis, regulates the expression of 
VEGF and promotes angiogenesis, which is essential for fulfilling the metabolic 
requirements of tumor growth (Forsythe et al., 1996). 
3. Vascular endothelial growth factor (VEGF): Structure and function 
VEGF (also referred to as VEGF-A) is a dimeric protein that has been shown to stimulate 
angiogenesis. As it also enhances vascular permeability, VEGF is also recognized as vascular 
permeability factor (VPF) (Ferrara & Kerbel, 2005). 
VEGF is a member of the VEGF/PDGF gene family. Other members of this family include 
VEGF-B, VEGF-C, VEGF-D, PDGF, and PIGF (Ferrara & Kerbel, 2005). VEGF exerts its 
biological effects by interacting with the VEGF receptors (VEGFR) present on the cell surface 
(Figure 1). These transmembrane receptors include VEGFR-1 (also known as Flt-1) and 
VEGFR-2 (Flk-1), which are predominantly expressed on vascular endothelial cells. A third 
receptor, VEGFR-3 (Flt-4), is mainly involved in the regulation of lymphatic systems 
(Karkkainen et al., 2001). The binding of VEGF to its receptor causes the dimerization and 
phosphorylation of intracellular receptor kinases, which in turn activates a cascade of 
downstream signals responsible for tumor angiogenesis (Ferrara & Kerbel, 2005).  
 
 
Fig. 1. VEGF signaling. 
4. Role of VEGF in epithelial ovarian cancer: Preclinical findings 
4.1 VEGF expression in epithelial ovarian cancer 
VEGF expression in epithelial ovarian cancer has been intensively examined (Wong et al., 
2003; Yamamoto et al., 1997; Brustmann, 2004; Mabuchi et al., 2010b). It has been generally 
accepted that VEGF expression is greater in ovarian cancers than in normal ovarian tissue or 
benign ovarian neoplasm. According to previous reports, in which common histological 
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subtypes such as serous adenocarcinoma or endometrioid adenocarcinoma were 
investigated, the expression rate of VEGF was approximately 90% (Wong et al., 2003; 
Yamamoto et al., 1997; Brustmann, 2004). In a recent report about clear cell carcinoma of the 
ovary, strong VEGF expression was observed in 86% of cases (Mabuchi et al., 2010b). These 
results suggest that most epithelial ovarian cancers are dependent on VEGF for tumor 
progression, and hence, are candidates for VEGF targeting therapy. 
4.2 VEGF expression and patient prognosis 
In patients with ovarian cancer, high serum VEGF levels are an independent risk factor for 
advanced stage and decreased survival (Mabuchi et al., 2010b; Cooper et al., 2002; Li et al., 
2004; Hefler et al., 2006). Moreover, previous immunohistochemical analyses have 
suggested that VEGF expression in ovarian cancer specimens is also associated with poor 
patient prognosis, advanced stage, and short survival (Mabuchi et al., 2010b; Cooper et al., 
2002; Li et al., 2004; Hefler et al., 2006). For example, in a recent investigation of ovarian clear 
cell carcinomas (Mabuchi et al., 2010b), patients whose tumor showed strong 
immunoreactivity displayed significantly shorter survival than those with weak 
immunoreactivity for VEGF (mean: 60 months vs. 40 months, respectively). The association 
observed between VEGF expression and clinical outcome in ovarian cancer patients makes 
the VEGF pathway an attractive therapeutic target in this patient group. 
4.3 VEGF expression and ascites formation 
The effect of VEGF on vascular permeability is believed to be crucial for malignant ascites 
formation (Senger et al., 1983; Zhang et al., 2002). In patients with ovarian cancer, high 
serum VEGF levels was reported to be an independent risk factor for developing ascites 
formation (Cooper et al., 2002; Li et al., 2004; Hefler et al., 2006). In an in vivo investigation 
using an intraperitoneal ovarian cancer model, VEGF inhibition resulted in the complete 
inhibition of ascites formation (Mesiano et al., 1998; Mabuchi et al., 2008). Since patients with 
advanced or recurrent ovarian cancer frequently suffer from malignant ascites and require 
paracentesis for symptomatic relief, the ability of VEGF-targeting agents to inhibit ascites 
formation makes them attractive candidate treatments for ovarian cancer (Numnum et al., 
2006). 
4.4 VEGF expression and chemoresistance 
It has been reported that chemoresistant tumors display greater VEGF expression than 
chemosensitive tumors (Mabuchi et al., 2010b; Schönau et al., 2007). For example, 5-
fluorouracil-resistant colon adenocarcinoma subclones were found to display increased 
VEGF expression and enhanced pro-angiogenic activity compared to the corresponding 
primary adenocarcinoma cells (Schönau et al., 2007). Moreover, cisplatin-refractory ovarian 
cancer cell lines exhibit higher VEGF expression than their parental cisplatin-sensitive cell 
lines (Mabuchi et al., 2010b). As VEGF increases vascular permeability, which leads to 
interstitial hypertension and the impaired delivery of cytotoxic agents to tumors; 
theoretically, increased VEGF production in chemoresistant tumors might further limit the 
efficacy of chemotherapy (Gerber & Ferrara, 2005). Therefore, VEGF inhibition is a 
reasonable treatment strategy for overcoming chemoresistance or enhancing the sensitivity 
of ovarian cancer to chemotherapeutic agents. 
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4.5 VEGF receptor expression in epithelial ovarian cancer 
VEGFR are predominantly expressed on vascular endothelial cells. However, recent reports 
have suggested that VEGFR are also expressed by some tumor cells including ovarian cancer 
cells (Sood et al., 2001; Spannuth et al., 2009). In a study by Spannuth et al, in situ hybridization 
revealed that VEGFR-1 and VEGFR-2 expression was observed in 85% and 15% of human 
ovarian cancer specimens, respectively. Moreover, using the ovarian cancer cell lines, the 
authors showed that functionally active VEGFR is present on most ovarian cancer cells 
(Spannuth et al., 2009). Although the biological role of the VEGFR expressed on tumor cells 
remains unclear, they might represent an additional target of ovarian cancer therapy. 
5. VEGF targeting agents 
It is generally accepted that, unlike normal vasculature, the intratumoral vessels produced 
by VEGF-mediated angiogenesis are hyperpermeable, leading to increased interstitial fluid 
pressure and the impaired perfusion of oxygen and cytotoxic agents into tumors. The 
resultant hypoxic conditions in tumor cells further increase the expression of VEGF and 
limit the efficacy of chemotherapy and radiotherapy (Gerber & Ferrara, 2005). Theoretically, 
the inhibition of VEGF by VEGF-targeting agents should inhibit neo-vascularization and 
“normalize” poorly formed, leaky intratumoral blood vessels. This could lead to the 
improved delivery of cytotoxic agents and oxygen to tumors (Gerber & Ferrara, 2005). 
There are two major strategies used to inhibit the VEGF pathway in cancer therapy 
(Spannuth et al., 2008). One is the inhibition of the VEGF ligand with antibodies or soluble 
receptors, and the other is the inhibition of the VEGF receptor with tyrosine kinase 
inhibitors (TKI) or receptor antibodies (Figure 2). Various VEGF-targeting agents have been 
identified and are currently being evaluated clinically or preclinically. Of these, 
bevacizumab, aflibercept, and several TKI are currently being evaluated in phase III clinical 
trials for the treatment of epithelial ovarian cancer (Table 1-2). 
 
 
Fig. 2. Strategy to inhibit VEGF signaling 
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6. Therapeutic potential of VEGF targeted agents in ovarian cancer: 
Preclinical findings 
Among the VEGF-targeting agents including bevacizumab, aflibercept, and TKI, 
bevacizumab has been used most commonly for the treatment of ovarian cancer in the 
clinical setting. Thus, we herein provide information regarding the preclinical activity of 
bevacizumab in ovarian cancer. 
6.1 Monotherapy 
Preclinical in vivo studies have demonstrated that inhibiting VEGF activity using a murine 
monoclonal antibody to human VEGF (A4.6.1) significantly inhibited the growth of 
subcutaneously inoculated ovarian tumors. Moreover, in mice carrying intraperitoneal 
tumors, treatment with A4.6.1 completely inhibited ascites production (Mesiano et al., 1998). 
Bevacizumab is the humanized form of A4.6.1, which was developed in 1997 (Presta et al., 
1997). In a preclinical investigation, treatment with bevacizumab significantly inhibited the 
growth of intraperitoneally inoculated serous ovarian cancer. In addition, bevacizumab 
treatment significantly inhibited ascites production and prolonged survival of the mice 
(Mabuchi et al., 2008). 
The single agent activity of bevacizumab on chemoresistant ovarian cancer has also been 
evaluated preclinically. According to a recent report, the growth inhibitory effect of 
bevaciumab on cisplatin-resistant ovarian cancer was similar to the effect of bevacizumab on 
cisplatin-sensitive ovarian cancer (Mabuchi et al., 2010b). Collectively, these results suggest 
that both platinum-sensitive and platinum-resistant ovarian cancer are the candidates for 
VEGF-targeting therapy. 
6.2 Combination therapy 
Not only to inhibit neo-vascularization, VEGF-targeted agents are believed to normalize 
intra-tumoral blood vessels and improved delivery of oxygen, nutrients, and cytotoxic 
agents (Gerber & Ferrara, 2005; Jain, 2005). Thus, theoretically, VEGF-targeting agents 
should be efficacious in combination with chemotherapy. 
In a mouse model of ovarian cancer, treatment with bevacizumab in combination with 
paclitaxel significantly reduced tumor growth compared with paclitaxel alone (83.3% 
reduction in the combination arm versus 58.5% reduction in the paclitaxel alone arm) and 
resulted in the complete inhibition of ascites formation (Hu et al., 2002). Similarly, 
treatment with bevacizumab in combination with cisplatin significantly reduced tumor 
growth and ascites formation compared with cisplatin therapy alone (Mabuchi et al., 
2008). 
6.3 Maintenance therapy 
There is a strong rationale for using angiogenesis targeted agents in the maintenance 
therapy setting. Since it has been reported that tumors require a vascular blood supply to 
grow beyond 2 mm (Gimbrone et al., 1972), any subclinical ovarian tumors that are present 
after a complete clinical response to first-line chemotherapy should require angiogenesis for 
their continued proliferation, invasion, and metastasis. Thus, VEGF-targeting maintenance 
therapy after standard primary treatment might be beneficial for patients with ovarian 
cancer. 
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The effect of VEGF-targeting agent as a maintenance therapy has been investigated in an in 
vivo ovarian cancer model (Mabuchi et al., 2008). In this investigation, athymic mice were 
intraperitoneally inoculated with serous ovarian cancer cells. When bevacizumab was used 
as a maintenance treatment after a complete clinical response to front-line chemotherapy 
had been obtained, bevacizumab significantly inhibited the recurrence of ovarian cancer and 
prolonged the survival of the mice (Mabuchi et al., 2008). This is the only preclinical report 
in which a survival benefit was derived from the use of a VEGF-targeting agent in the 
setting of maintenance therapy. 
7. VEGF targeting agents in ovarian cancer: A clinical trial review 
7.1 Bevacizumab 
To date, bevacizumab, a recombinant human monoclonal antibody to the VEGF ligand, is 
the most studied VEGF-targeting agent in patients with ovarian cancer (Eskander & 
Randall, 2011). 
7.1.1 Bevacizumab in the setting of front-line, maintenance, or salvage therapy 
The clinical activity of bevacizumab as a single agent has been prospectively examined in 
two phase II trials involving patients with recurrent ovarian cancer (Cannistra et al., 2007; 
Burger et al., 2007). The gynecologic oncology group (GOG) evaluated the efficacy of 
bevacizumab in a phase II clinical trial involving 62 patients with recurrent ovarian cancer 
(GOG 170-D). Of the patients enrolled, 3 patients showed a complete response, and 4 
patients demonstrated a partial response, giving an overall response rate of 18% and a 
median response duration of 10.25 months. Importantly, an additional 34 patients (55%) 
showed disease stabilization (Burger et al., 2007). Canninstra et al. also investigated the 
activity of single agent bevacizumab in 44 patients with platinum-resistant, heavily 
pretreated ovarian cancer. Of the 44 patients, according to the RECIST guidelines, there 
were no complete responders, but 7 partial responders were observed. The median duration 
of the response was 4.3 months (Cannistra et al., 2007). 
The effect of bevacizumab has also been examined in the setting of combination therapy in 
two phase II studies. Garcia et al. evaluated the activity of a combination of bevacizumab 
and oral cyclophosphamide in patients with recurrent ovarian cancer. Of the 70 patients 
enrolled, 17 patients (24%) demonstrated a partial response, and 44 patients (63%) showed 
disease stabilization (Garcia et al., 2008). Penson et al. recently reported on the efficacy of 
bevacizumab in combination with carboplatin and paclitaxel as a first-line chemotherapy for 
patients with advanced Mullerian tumors, most of which (73%) were ovarian cancers.  Of a 
total of 28 patients with measurable disease, 11 patients (39%) demonstrated a complete 
response, and 10 patients (36%) showed a partial response (Penson et al., 2010). 
The evidence of clinical activity found in these phase II studies has led to the development 
of phase III trials examining the use of bevacizumab for the treatment of ovarian cancer 
(Teoh & Secord, 2011; Burger, 2011) (Table 1). 
The efficacy of Bevacizumab in combination with carboplatin and paclitaxel as a primary 
treatment is being evaluated in three phase III trials. The first is a three-arm placebo-
controlled trial, GOG 218 (NCT00262847): a 3-armed trial designed to investigate the clinical 
benefit of adding bevacizumab to front-line carboplatin-paclitaxel chemotherapy, as well as 
the benefit of bevacizumab maintenance therapy in patients with advanced stage epithelial 
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ovarian, primary peritoneal, or fallopian tube cancer (Figure 3). After a median follow-up 
period of 17.4 months, the preliminary results from 1873 patients were presented at the 2010 
meeting of the American Society of Clinical Oncology (ASCO) (Burger et al., 2010). The 
patients who were treated with concurrent or maintenance bevacizumab showed 
significantly longer PFS than the standard chemotherapy arm (14.1 months versus 10.3 
months; hazard ratio, 0.717; 95% confidence interval, 0.625-0.824; p<0.0001). No significant 
difference in PFS was observed between the patients treated with concurrent bevacizumab 
and those treated with standard chemotherapy (11.2 months versus 10.3 months; HR, 0.908; 
95% CI, 0.759-1.040; p=0.008). The OS data were not mature at the time of the presentation 
due to the cohort suffering a mortality rate of 24%. 
 
Study Setting Trial design Status Outcome 
GOG 218 First-line 
adjuvant 
Arm 1: CT 
 
Arm 2: CT+Bev 
 
Arm 3: CT+Bev+maintenance Bev 
Completed 
accrual 
Favoring 
Arm 3; 
HR 0.717; 
p<0.0001. 
ICON-7 First-line 
adjuvant 
Arm 1: CT 
 
Arm 2: CT+Bev+maintenance Bev 
Completed 
accrual 
Favoring 
arm 2;  
HR 0.81; 
p<0.0041. 
GOG 252 First-line 
adjuvant 
Arm 1: PTX (iv,d1, 8, 15)+ 
             CBDCA (iv,d1)+ Bev+ 
             maintenance Bev 
 
Arm 2: PTX (iv, d1, 8, 15)+ 
             CBDCA (ip, d1)+Bev+ 
             maintenance Bev 
 
Arm 3: PTX (iv,d1)+ PTX (ip, d8)+ 
             CDDP (ip, d2)+ 
             Bev+maintenance Bev 
Open to 
accrual 
 
GOG 213 Recurrent Arm 1: CT 
 
Arm 2: CT+Bev+maintenance Bev 
Open to 
accrual 
 
OCEANS Recurrent Arm 1: CG 
 
Arm 2: CG+Bev+maintenance Bev 
Completed 
accrual 
Results not 
yet 
available 
AURELIA Recurrent Arm 1: PTX, Topo, or PLD 
 
Arm 2: PTX, Topo, or PLD+Bev 
Open to 
accrual 
 
Table 1. Summary of randomized controlled trials evaluating bevacizumab in ovarian 
cancer. CT, carboplatin plus paclitaxel; CG, carboplatin plus gemcitabine, Bev, bevacizumab, 
PTX, paclitaxel; CBDCA, carboplatin; CDDP, cisplatin; Topo, topotecan; PLD, liposomal 
doxorubicin; HR, hazard ratio. 
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Fig. 3. GOG 218 schema. 
The second study is a non-placebo-controlled trial organized by the International 
Collaborative Ovarian Neoplasm trial, ICON7 (NCT00483782). This study is 2-armed trial 
designed to compare carboplatin-paclitaxel with bevacizumab plus carboplatin-paclitaxel 
followed by maintenance bevacizumab therapy in patients with stage IIB-IV or early-stage 
high-risk ovarian (stage I-IIa with grade 3 or clear cell histology), primary peritoneal, or 
fallopian tube cancer (Figure 4). Data from the 1528 patients enrolled in this trial were 
presented at European Society of Medical Oncology meeting (ESMO) in 2010 (Perren et al 
2010). The patients that were treated with concurrent and maintenance bevacizumab had a 
median PFS of 19 months, which was longer than the 17.3 months observed in the patients 
treated with chemotherapy alone (HR, 0.81; 95% CI, 0.70-0.94; p<0.0041). The result of 
interim analysis presented at the 2011 meeting of the ASCO also showed the superiority of 
the concurrent and maintenance bevacizumab compared to the standard chemotherapy 
(median PFS of 19.8 months versus 17.4 months; HR, 0.87; 95% CI, 0.77-0.99; p=0.039). 
Survival data will not be mature until 2013 (Kristensen et al., 2011). 
 
 
Fig. 4. ICON7 schema. 
The last trial is GOG252 (NCT00951496), which will not determine the efficacy of additional 
bevacizumab, but rather is designed to compare intravenous versus intraperitoneal 
carboplatin, and intraperitoneal carboplatin versus intraperitoneal cisplatin plus paclitaxel 
in the setting of front-line therapy. All participants received bevacizumab in the front-line 
setting as well as bevacizumab consolidation chemotherapy (Figure 5). 
www.intechopen.com
 
VEGF Targeting Agents in Ovarian Cancer 
 
343 
 
Fig. 5. GOG 252 schema. 
The activity of bevacizumab in patients with recurrent ovarian cancer is currently being 
evaluated in several phase III trials. GOG 213 (NCT00565851) was designed to evaluate the 
roles of secondary cytoreductive surgery and bevacizumab in combination with carboplatin-
paclitaxel in patients with platinum-sensitive recurrent ovarian cancer (Figure 6). 
 
 
 
Fig. 6. GOG 213 schema. 
The Ovarian Cancer Evaluation of Avastin and Safety-AVF4095g trial (OCEANS) is a phase 
III study designed to compare gemcitabine and carboplatin with or without bevacizumab in 
patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube 
cancer (NCT00434642). After 6 cycles of combination chemotherapy with carboplatin-
gemcitabine, the patients will continue to receive bevacizumab or placebo consolidation 
therapy for up to 51 weeks (Figure 7). After a median follow-up period of 24 months, 
preliminary results from 484 patients were presented at the 2011 meeting of the ASCO 
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(Aghajanian et al., 2011). Patients treated with concurrent and maintenance bevacizumab 
showed significantly longer PFS compared to the standard chemotherapy arm (12.4 months 
versus 8.4 months; hazard ratio, 0.484; 95% Cl, 0.388-0.605; p<0.0001). The survival data are 
not mature. 
 
 
 
Fig. 7. OCEANS schema. 
The AURELIA study (NCT00976911) is a phase III study designed to evaluate the benefit of 
adding bevacizumab to standard chemotherapy in patients with recurrent epithelial 
ovarian, fallopian tube, or primary peritoneal cancer who displayed disease progression 
within 6 months of platinum therapy. The patients will receive paclitaxel, topotecan, or 
liposomal doxorubicin with or without concomitant bevacizumab (Figure 8). 
 
 
 
Fig. 8. AURELIA schema. 
7.1.2 Bevacizumab for palliative treatment 
The ability of bevacizumab as a palliative agent for symptomatic ascites has also been 
evaluated in several studies. In a report by Numnum et al, treatment with bevacizumab for 
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patients with recurrent ovarian cancer with symptomatic ascites resulted in relief of 
symptoms associated with ascites formation. Moreover, objectively, no patient required a 
paracentesis after the initiation of bevacizumab therapy (Numnum et al., 2006). These 
results suggest that it is reasonable to consider the use of bevacizumab as a palliative agent 
in patients with end stage ovarian cancer with symptomatic ascites. 
7.2 Aflibercept (AVE0005/VEGF trap) 
Aflibercept (AVE0005/VEGF trap) is a fusion protein that inactivates VEGF by acting as a 
decoy receptor for VEGF, preventing VEGF binding to VEGFR. Preclinical in vivo studies 
have demonstrated that treatment with aflibercept resulted in a decreased tumor burden 
and reduced ascites formation as a result of tumor angiogenesis inhibition (Byrne et al., 
2003). 
The clinical activity of aflibercept in ovarian cancer has been evaluated in several phase I/II 
studies (Moroney et al., 2009). In a randomized, double-blind, phase II study of patients 
with recurrent ovarian cancer, aflibercept produced a significant tumor response (according 
to the RECIST criteria) or CA-125 response (defined as a 50% reduction in the CA-125 
protein level) was observed in 18 (13.8%) out of 130 evaluable patients. In addition, of the 40 
patients who had evaluable ascites at the baseline, 77.5% demonstrated the complete 
disappearance or stabilization of their ascites (Tew et al., 2007). 
On the basis of the promising results from these preclinical and clinical investigations, 
aflibercept has been evaluated in a phase III trial (Table 2). In this trial, the effect of 
aflibercept on the necessity of repeated paracentesis for symptomatic ascites in patients with 
advanced ovarian cancer has been evaluated (NCT00327444) (Figure 9). 
 
 
Fig. 9. NCT00327444 schema. 
7.3 Tyrosine kinase inhibitors 
Another strategy is the inhibition of the VEGF receptor using tyrosine kinase inhibitors 
(Teoh & Secord, 2011). In contrast to the specific inhibition of the VEGF pathway using 
bevacizumab or aflibercept, most TKI target multiple receptors responsible for tumor-
angiogenesis. Theoretically, these multi-targeting anti-angiogenic agents inhibit tumor 
angiogenesis more completely than agents that specifically target VEGF, and thus, might 
have a greater therapeutic benefit. Several TKI have demonstrated clinical activity in phase 
I/II trials involving patients with ovarian cancer and are currently being evaluated in phase 
III trials (Table 2). 
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Compound Target Setting Patients Endopoint Status 
Aflibercept VEGF Recurrent Arm 1: Placebo 
 
Arm 2: Aflibercept 
Time to 
repeat 
para-
centesis 
Completed 
Results  
not yet 
available 
Cediranib VEGFR
-1,2,3 
PDGFR
- 
c-kit 
Recurrent Arm 1: CT 
 
Arm 2: CT+Ced 
 
Arm 3: CT+Ced+ 
maintenance Ced 
PFS and 
OS 
Open to 
accrual 
Pazopanib VEGFR
-1,2,3 
PDGFR
- 
c-kit 
Maintenance*  Arm 1: Placebo 
 
Arm 2: Pazopanib 
PFS Completed 
accrual 
BIBF 1120 VEGFR
-1,2,3 
PDGFR
 
FGFR-
1,2,3 
Front-line 
adjuvant 
Arm 1: CT 
 
Arm 2: CT+BIBF 
1120 
PFS Open to 
accrual 
 
Table 2. Summary of the randomized controlled trials evaluating the efficacy of tyrosine 
kinase inhibitors against ovarian cancer. Ced, Cediranib; PFS, progression free survival; OS, 
overall survival. 
* Maintenance treatment for patients whose cancer had not progressed during first line 
chemotherapy. 
7.3.1 Cediranib 
Cediranib is an oral TKI that targets all three VEGFR, PDGFR, and c-kit. In the setting of a 
phase II study of patients with recurrent epithelial ovarian cancer or fallopian tube cancer, 
cediranib demonstrated significant clinical activity. In this trial, single agent cediranib 
showed a clinical benefit rate (complete response, partial response, stable disease, or CA125 
non-progression) of 30% (Matulonis et al., 2009).  
Cediranib is currently being evaluated in a phase III trial (ICON6), which was designed to 
investigate the clinical benefit of adding cediranib to carboplatin-paclitaxel, as well as the 
benefit of continuing cediranib as a maintenance therapy in patients with platinum-
sensitive, recurrent ovarian cancer (NCT00532194) (Figure 10). 
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Fig. 10. NCT00532194 schema. 
7.3.2 Pazopanib 
Pazopanib, an oral TKI that targets all three VEGFR, PDGFR, and c-kit, was approved by the 
United States Food and Drug Administration in 2009 for the treatment of patients with 
advanced renal cell carcinoma. The clinical activity of pazopanib in ovarian cancer has been 
evaluated in several phase I/II trials (Monk et al., 2010; Friedlander et al., 2010). In a phase II 
trial in which the CA-125 response (>50% decrease from baseline) was the primary 
endpoint, pazopanib demonstrated a CA-125 response rate of 31% (11 out of 36 patients). In 
17 patients with measurable disease, the overall response rate (according to the RECIST 
criteria) was 18%. 
On the basis of these results, the activity of pazopanib is currently being evaluated in a 
phase III study, which was designed to compare the efficacy of pazopanib versus placebo in 
women whose disease had not progressed after first-line chemotherapy for epithelial 
ovarian, fallopian tube, or primary peritoneal cancer (NCT00866697) (Figure 11). 
 
 
Fig. 11. NCT00866697 schema. 
7.3.3 BIBF 1120 
BIBF 1120 is an orally available TKI that binds and inhibits VEGFR, PDGFR, and FGFR 
tyrosine kinases. On the basis of a promising randomized controlled phase II trial 
highlighting the benefit of maintenance treatment with BIBF 1120 after salvage 
chemotherapy in patients with recurrent ovarian cancer (Ledermann et al., 2009), the 
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Arbeitsgemeinschaft Gynakologische Oncologie (AGO) is currently conducting a Phase III 
trial (AGO-OVAR-12). This trial was designed to evaluate the efficacy of BIBF 1120 in 
combination with carboplatin-paclitaxel in patients with advanced epithelial ovarian cancer 
in the setting of front-line treatment (NCT01015118) (Figure 12). 
 
 
Fig. 12. NCT01015118 schema. 
8. Toxic effects of VEGF-targeting agents 
As VEGF mediates physiologically important processes in healthy tissues, VEGF-targeting 
agents are associated with unique and potentially problematic side effects (Stone et al., 
2010). 
Hypertension is the most common side effect of VEGF-targeting agents. It typically occurs 
within 3 weeks of the beginning of therapy. The pathogenesis of hypertension associated 
with VEGF-targeting agents is not fully understood. However, it is speculated that the 
suppression of nitric oxide production by VEGF antagonism leads to vasoconstriction and 
decreased sodium ion renal excretion, which results in elevated blood pressure (Izzedine 
et al., 2009). A recent review of the adverse effects of anti-angiogenic therapies suggested 
that the incidence of grade 3/4 hypertension in patients that had been treated with 
bevacizumab, aflibercept, or TKI was 8-26%, 9-32%, and 5-48%, respectively (Stone et al., 
2010). 
Proteinuria is another common side effect observed in patients treated with bevacizumab or 
aflibercept. In clinical trials of bevacizumab or aflibercept, grade 3/4 proteinuria occurred in 
approximately 1-4% of patients (Izzedine et al., 2010). Proteinuria is rare in patients treated 
with TKI. Such proteinuria is reported to occur as a result of the disruption of VEGF-
dependent glomerular endothelial integrity (Ostendorf et al., 1999). 
Wound healing complications is another serious side effect that is reported to occur in 
patients treated with VEGF-targeting agents. As the wound-healing process is dependent on 
angiogenesis, VEGF-targeting agents have the potential to delay the wound-healing process 
in patients who undergo surgery. On the basis of a previous report suggesting that patients 
who undergo surgery within 28-60 days of bevacizumab therapy are at an increased risk of 
wound-healing complications, physicians recommend avoiding major surgery at least 30 
days after the completion of bevacizumab treatment (Shord et al., 2009). 
The increased risk of atrial thromboembolic events (ATE), usually myocardial or 
cerebrovascular events, is another serious adverse effect associated with bevacizumab 
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therapy. In a recent analysis of 1745 patients with colorectal, breast, or non-small-cell lung 
cancer from five randomized trials, the addition of bevacizumab to chemotherapy was 
associated with an increased risk of ATE (incidence of 3.8% in the combination therapy 
group vs 1.7% in the chemotherapy alone group) (Scappaticci et al., 2007). The precise 
incidence of ATE in patients with ovarian cancer who have been treated with VEGF-
targeting agents is unknown; however, so far, 30 ATE events have been reported. ATE 
events are rarely reported in patients who have been treated with aflibercept or TKI (Stone 
et al., 2010). 
The most serious complication of VEGF-targeting agents is bowel perforation. In a recent 
review of 9 clinical studies examining the use of bevacizumab in ovarian cancer patients, the 
overall frequency of bowel perforation was 5.4%, which was higher than the 2.4% observed 
in patients with colorectal cancer (Han & Monk, 2007). Bowel perforation was also observed 
in patients that had been treated with aflibercept (Colombo et al., 2008), however, there have 
been no reported cases of bowel perforation involving patients that were treated with TKI 
monotherapy (Stone et al., 2010). The management of bowel perforation is difficult because 
of the increased likelihood of surgical and postoperative complications, such as thrombosis 
or compromised wound healing caused by bevacizumab treatment, suggesting the 
importance of preventing this serious complication. The precise mechanisms of, and risk 
factors for, bowel perforation are largely unknown. However, Simpkins et al. suggested 
from their experience that bowel perforation can be avoided by carefully selecting patients 
without clinical symptoms of bowel obstruction, evidence of rectosigmoid involvement on a 
pelvic examination, or evidence of bowel involvement on a computed tomography (CT) 
scan (Simpkins et al., 2007). 
At this point, no standard recommendations exist for the management of the adverse effects 
induced by VEGF-targeting agents. Further investigations are needed to solve this issue. 
9. Conclusions and future directions 
Recent increases in our understanding of cancer biology and the molecular pathways that 
control tumor angiogenesis have led to the identification of novel VEGF-targeting agents 
that can be used to treat ovarian cancer. Although VEGF-targeting agents have yielded 
promising results in ovarian cancer in the settings of front-line treatment and salvage 
treatment, several important clinical issues remain unanswered. The optimal methods for 
evaluating the efficacy of VEGF-targeting agents have yet to be clarified. As VEGF-
targeting agents have cytostatic rather than cytotoxic effects, the traditional criteria 
applied to cytotoxic agents, such as the RECIST criteria, might be less applicable. The 
identification of surrogate biomarkers that can be used to guide drug choice or optimal 
dosing or to predict the tumor response or drug resistance is of paramount importance. In 
addition, increased understanding of the mechanisms underlying the unique toxic effects 
of VEFG-targeting agents, as well as the development of evidence-based management 
strategies for these adverse effects, are also necessary. Choosing the optimal VEGF-
targeting agent for each patient will extend patient survival without reducing quality of 
life in the near future. 
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